Vector Labs Ab03368-23.0 Anti-HLA-DR [L243], Rabbit IgG, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: L243
Synonyms: CD74; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33
Amount: 200 μg
Application Codes Clone: FC; IF; IP; WB; ICC; IHC; block; in vivo; ELISA
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format for improved compatibility with existing reagents assays and techniques.
Specificity Statement: This antibody specifically reacts with the HLA-DR antigen and does not cross-react with HLA-DP or HLA-DQ. It binds to a conformational epitope on HLA-DRα, which requires the proper folding of the αβ heterodimer. HLA-DR, a major histocompatibility complex (MHC) class II cell surface receptor, is encoded by the human leukocyte antigen complex located on chromosome 6 at region 6p21.31. HLA-DR plays a key role in autoimmune conditions, influencing both disease susceptibility and resistance. Its primary function is to present peptide antigens, including those of foreign origin, to the immune system. This process helps elicit or suppress T-helper cell responses, which eventually lead to the production of antibodies against the specific peptide antigen.
Application Notes: This antibody can be used for the immunoprecipitation of HLA-DR and MHC class-II peptides (Bonnefoy et al., 1988; PMID: 2961843). This antibody selectively inhibited the in vitro proliferation of Epstein-Barr virus-transformed lymphoblastoid cell lines (Kabelitz and Janssen, 1989; PMID: 2467753). This antibody can also be used for the immunocytochemical and immunohistochemical analysis of frozen sections of necropsy brain tissue to identify HLA-DR-expressing cells (Esiri et al., 1991; PMID: 1864982). This antibody was used in the detection of MHC class II protein in a western blot (Esser et al., 2001; PMID: 11390619). This antibody was used in a flow cytometric assay to detect the decrease in HLA-DR expression on monocytes, which is an indicator of immunosuppression in patients with sepsis and is correlated with an increased risk of secondary infection and mortality (Quadrini et al., 2021; PMID: 33432735). Alexa 568- and FITC-labeled versions of this antibody were used in the immunofluorescent staining of renal microvascular endothelial cells (RMEC) or human kidney tissue (Muczynski et al., 2003; PMID: 12707403). This antibody was assessed in a pilot study using a canine lymphoma model. In vitro studies showed that this antibody binds to both healthy and lymphoma canine lymphocytes, inducing apoptosis in canine non-Hodgkin lymphoma cells. In vivo studies confirmed the antibody's safety in healthy and lymphoma-affected dogs, as well as its binding activity in lymphoma-affected lymph nodes. Preliminary results indicated transient disease stabilization in a subset of dogs with advanced lymphoma (Stein et al., 2011; PMID: 21133722).

Product Class:	Purified
Clone ID:	L243
Synonyms:	CD74; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33
Amount:	200 μg
Application Codes Clone:	FC; IF; IP; WB; ICC; IHC; block; in vivo; ELISA
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format for improved compatibility with existing reagents assays and techniques.
Specificity Statement:	This antibody specifically reacts with the HLA-DR antigen and does not cross-react with HLA-DP or HLA-DQ. It binds to a conformational epitope on HLA-DRα, which requires the proper folding of the αβ heterodimer. HLA-DR, a major histocompatibility complex (MHC) class II cell surface receptor, is encoded by the human leukocyte antigen complex located on chromosome 6 at region 6p21.31. HLA-DR plays a key role in autoimmune conditions, influencing both disease susceptibility and resistance. Its primary function is to present peptide antigens, including those of foreign origin, to the immune system. This process helps elicit or suppress T-helper cell responses, which eventually lead to the production of antibodies against the specific peptide antigen.
Application Notes:	This antibody can be used for the immunoprecipitation of HLA-DR and MHC class-II peptides (Bonnefoy et al., 1988; PMID: 2961843). This antibody selectively inhibited the in vitro proliferation of Epstein-Barr virus-transformed lymphoblastoid cell lines (Kabelitz and Janssen, 1989; PMID: 2467753). This antibody can also be used for the immunocytochemical and immunohistochemical analysis of frozen sections of necropsy brain tissue to identify HLA-DR-expressing cells (Esiri et al., 1991; PMID: 1864982). This antibody was used in the detection of MHC class II protein in a western blot (Esser et al., 2001; PMID: 11390619). This antibody was used in a flow cytometric assay to detect the decrease in HLA-DR expression on monocytes, which is an indicator of immunosuppression in patients with sepsis and is correlated with an increased risk of secondary infection and mortality (Quadrini et al., 2021; PMID: 33432735). Alexa 568- and FITC-labeled versions of this antibody were used in the immunofluorescent staining of renal microvascular endothelial cells (RMEC) or human kidney tissue (Muczynski et al., 2003; PMID: 12707403). This antibody was assessed in a pilot study using a canine lymphoma model. In vitro studies showed that this antibody binds to both healthy and lymphoma canine lymphocytes, inducing apoptosis in canine non-Hodgkin lymphoma cells. In vivo studies confirmed the antibody's safety in healthy and lymphoma-affected dogs, as well as its binding activity in lymphoma-affected lymph nodes. Preliminary results indicated transient disease stabilization in a subset of dogs with advanced lymphoma (Stein et al., 2011; PMID: 21133722).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews